**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a retrospective study involving 72 patients conducted between December 2012 and December 2016, 71 patients including one male patient \[*ages not stated; not all sexes stated*\] were described, who developed various bacterial, viral or fungal infections while receiving immunosuppressive treatment with cyclophosphamide, ciclosporin and mycophenolate mofetil. Additionally, of the 71 patients, 36 patients died due to the infections or its complications \[*routes and duration of treatments to reaction onsets not stated; not all dosages stated*\].

The patients, who underwent haploidentical haematopoietic cell transplantation (haplo-HCT) for an unspecified underlying condition [1](#Fn1){ref-type="fn"} , started receiving GvHD prophylaxis with cyclophosphamide 50 mg/kg/day. Additionally, they received immunosuppressive treatment with ciclosporin \[ciclosporin-A\] and mycophenolate mofetil. After (negative)2−716 days after haplo-HCT, the patients developed various bacterial, viral or fungal infections that included *Pseudomonas aeruginosa*pneumonia (n=3), *Staphylococcus haemolyticus* infection (n=2), central line-associated bloodstream infection (n=24), *Pseudomonas aeruginosa*infection (n=22), cytomegalovirus reactivation (n=43), adenovirus infection (n=1), BK virus infection (n=3), Epstein-Barr virus infection (EBV; n=49), hepatitis-B virus reactivation (HBV; n=1), human herpes virus-6 infection (HHV6; n=50), *Staphylococcus aureus* infection (n=1), *Corynebacterium diphtheriae*infection (n=1), multi-drug resistant *Enteroccocus faecium*infection (n=3), mucormycosis (n=3), *Streptococcus parasanguinis*infection (n=1), *Clostridium difficile*colitis (n=4), *Pseudomonas mosselii*infection (n=1), *Legionella*pneumonia (n=1), aspergillus infection (n=17), *Klebsiella pneumoniae*infection (n=8), methicillin-resistant *Staphylococcus aureus*infection (n=1), *Candida albicans*infection (n=9), *Staphylococcus epidermidis*infection (n=2), *Pseudomonas putida*infection (n=1), multi-drug resistant *Staphyloccocus warneri*infection (n=1), streptoccocus-B infection (n=1), *Escherichia coli*infection (n=9), herpes simplex (n=1), *Stenotrophomonas maltophilia*infection (n=3), toxoplasmosis (n=3), *Candida parapsilosis*infection (n=1), *Streptococcus mitis*infection (n=1), *Candida mitis*infection (n=1), *Clostridium tertium*infection (n=1), *Klebsiella oxytoca*infection (n=1), *Staphylococcus hominis*infection (n=3), *Acinetobacter johnsonii*infection (n=1), perianal cellulitis (n=1), *Pneumocystis jiroveci*pneumonia (PJP; n=6), *Scedosporium*infection (n=1), *Haemophilus influenzae*infection (n=1), pansinusitis (n=1), gram-negative bacilli infection (n=1), *Kluyvera ascorbata*infection (n=1), *Candida dubliniensis*infection (n=1), *Blastomyces dermatitidis*infection (n=1), *Candida glabrata*infection (n=1) or BK virus cystitis (n=1). Additionally, 15 of the 71 patients developed septic shock (4 patients), cardiogenic shock (1 patient), posterior reversible encephalopathy syndrome (PRES; 2 patients), progressive multifocal leukoencephalopathy (PML; 1 patient), thrombotic microangiopathy (1 patient), status epilepticus (1 patient), pneumonia (1 patient), acute respiratory distress syndrome (ARDS; 3 patients) and post-transplant lymphoproliferative disease (PTLD; 2 patients).

The male patient, who had developed HBV reactivation, had been receiving entecavir prior to haplo-HCT that was switched to tenofovir, and a rapid effective clearance of HBV was achieved. Of the two patients, who had developed EBV-related PTLD, one was treated with rituximab and achieved a complete remission. The other patient with PTLD was successfully treated with one course of rituximab with cyclophosphamide, vincristine and prednisone, followed by three courses of rituximab alone. Five patients, who had developed HHV6, were treated with immune globulin (2 patients) and foscavir (3 patients). In the patient with PML, ciclosporin was stopped, after which the neurologic symptoms improved with no further recurrence. Of the 71 patients, 36 patients died due to multi-drug resistant *P. aeruginosa*pneumonia (2 patients), herpes simplex (1 patient), PJP (1 patient), septic shock (3 patients), *Candida albicans*infection (1 patient), ARDS (1 patient), severe BK virus cystitis, septic shock and status epilepticus (1 patient), multi-drug resistant *P. aeruginosa*infection, *Candida albicans*infection and cardiogenic shock (1 patient), septic shock and PRES syndrome (1 patient), *P. aeruginosa*infection (1 patient), TMA, *Staphylococcus haemolyticus*infection, central line-associated bloodstream infection, HHV6 infection, *Candida albicans*infection and *Candida glabrata*infection (1 patient), relapse/progressing disease (13 patients), GvHD and ARDS (2 patients), GvHD and mucormycosis (1 patient), GvHD and pneumonia (1 patient), GvHD (3 patients), GvHD, aspergillus infection and BK virus infection (1 patient) or GvHD and *P. aeruginosa*pneumonia (1 patient) \[*not all outcomes stated*\].

**Author comment:** *\"\[Post-transplant cyclophosphamide\] seems to be associated with an increased incidence of infectious complications, suggesting an enhanced and prolonged immunosuppression\".*

The underlying condition of patients\' is not specified in the source document.
